Authors: Amy Hughes, Amanda Gentry, John Merriman, Susan Sereika, Yehui Zhu, and Catherine Bender Faculty Mentor: Catherine Bender University of Pittsburgh School of Nursing 3500 Victoria St, Pittsburgh, PA 15213

Background: Breast cancer is the second most common form of cancer in postmenopausal women. At least 5 years of aromatase-inhibitor (AI) therapy improve disease-free and overall survival. However, it’s associated multiple side effects including changes in cognitive function may impact treatment adherence. Purpose: The purpose of this secondary analysis is to explore the relationship between self-reported cognitive function and adherence to therapy among postmenopausal women with breast cancer during the first year of AI therapy. Methods: Participants were postmenopausal women with early stage breast cancer receiving AI therapy. Self-reported cognitive function was measured with the Patient Assessment of Own Functioning Inventory (PAOFI) at pre-AI therapy and 6-months post-therapy initiation. Higher total scores indicate poorer self-reported cognitive function. AI therapy adherence was assessed using the Medication Event Monitoring System summarized as the percentage of days adherent during the first and second 6-month periods. Spearman correlation coefficients were generated for relationships between: a) PAOFI total score at baseline and adherence during the first 6 months of AI therapy, and b) PAOFI total score at 6-months post-initiation of therapy and adherence during the second 6 months of AI therapy. Results: Participants were, on average, 61 years of age (SD 6.1) with 15 years of education (SD 2.8); 70.6% were partnered, 97% were white, and 67% were diagnosed with stage I breast cancer. Results showed small negative but significant correlations between pre-AI self-reported cognitive function and the first 6 months of AI adherence (r=-.204; p=.001) and self-reported cognitive function at 6-months post-AI initiation and the second 6 months of adherence (r=-.179; p=.009), where poorer perceived cognitive function was associated with poorer adherence. Conclusions: Our findings suggest that poorer self-reported cognitive function may in part predict poorer adherence to endocrine therapy in the following 6 months of endocrine therapy in postmenopausal women with breast cancer.

Additional Abstract Information

Presenter: Amy Hughes

Institution: University of Pittsburgh School of Nursing

Type: Oral

Subject: Nursing

Status: Approved

Time and Location

Session: Oral 9
Date/Time: Fri 4:20pm-4:40pm
Location: Old North 211
List other presenters in this same room and session